SEA PHARMA CONSULTANCY PTE. LTD.

<p><strong>Indications</strong><br> Adrenocortical insufficiency (Addison&rsquo;s disease), diminution of anterior pituitary function (hypopituitarism), congenital adrenal hyperplasia.<br> Conditions where systemic glucocorticoid therapy is indicated.</p>

<p><strong>INDICATIONS &amp; USAGE:</strong><br> <em>Secondary prevention of atherothrombotic events</em><br> Clopidogrel is indicated in:</p> <ul> <li>Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.</li> <li>Adult patients suffering from acute coronary syndrome: <ul class="dash"> <li>Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).</li> <li>ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.</li> </ul> </li> </ul> <p><em>In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)</em><br> Clopidogrel in combination with ASA is indicated in:</p> <ul class="dash"> <li>Adult patients with moderate to high-risk TIA (ABCD2¹ score &ge;4) or minor IS (NIHSS² &le;3) within 24 hours of either the TIA or IS event.</li> </ul> <p><em>Prevention of atherothrombotic and thromboembolic events in atrial fibrillation</em><br> In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.<br> In patients with AF at increased risk of vascular events who can take VKA therapy, VKA has been shown to result in better clinical benefit than ASA alone or the combination of clopidogrel and ASA for reductions of stroke.</p> <p>For further information please refer to section 5.1 &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>.<br> ¹ Age, Blood pressure, Clinical features, Duration, and Diabetes mellitus diagnosis<br> ² National Institutes of Health Stroke Scale</p>

<p><strong>1. What HARUFEN is and what it is used for</strong><br> HARUFEN contains ketoprofen, a non-steroidal anti-inflammatory drug which works by reducing the pain in your skin.<br> HARUFEN is used for relief of pain and inflammation of the following diseases or symptoms:</p> <ul class="dash"> <li>Arthritis deformans.</li> <li>Periarthritis of shoulder.</li> <li>Tendonitis.</li> <li>Peritendinitis.</li> <li>Humeral epicondylitis (tennis elbow etc.).</li> <li>Muscle pain.</li> <li>Swelling and posttraumatic swelling and pain.</li> </ul>

<p><strong>4.1 Therapeutic indications</strong></p> <p><strong>Adult indication</strong><br> Entevir is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</p> <p>The following points should be considered when initiating therapy with Entevir:</p> <ul> <li>This indication is based on histologic, virologic, biochemical, and serologic responses in nucleoside-treatment-na&iuml;ve and lamivudine-resistant adult subjects with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease.</li> <li>Virologic, biochemical, serologic, and safety data are available from a controlled study in adult subjects with chronic HBV infection and decompensated liver disease (see section 4.4 &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</li> <li>Virologic, biochemical, serologic, and safety data are available for a limited number of adult subjects with HIV/HBV co-infection who have received prior lamivudine therapy (see sections 4.2, 4.4 and 5.1 &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</li> </ul> <p><strong>Paediatric population</strong><br> Safety and effectiveness of entecavir in pediatric patients below the age of 16 years have not been established.</p>

<p><strong>4.1 Therapeutic indications</strong></p> <p><strong>Adult indication</strong><br> Entevir is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</p> <p>The following points should be considered when initiating therapy with Entevir:</p> <ul> <li>This indication is based on histologic, virologic, biochemical, and serologic responses in nucleoside-treatment-na&iuml;ve and lamivudine-resistant adult subjects with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease.</li> <li>Virologic, biochemical, serologic, and safety data are available from a controlled study in adult subjects with chronic HBV infection and decompensated liver disease (see section 4.4 &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</li> <li>Virologic, biochemical, serologic, and safety data are available for a limited number of adult subjects with HIV/HBV co-infection who have received prior lamivudine therapy (see sections 4.2, 4.4 and 5.1 &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</li> </ul> <p><strong>Paediatric population</strong><br> Safety and effectiveness of entecavir in pediatric patients below the age of 16 years have not been established.</p>